Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solifenacin Effect on Bladder Wall Thickness and Urinary NGF in Female Overactive Bladder with Detrusor Overactivity
DRKS00003889Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 20
01
Overview
Phase 4, randomised, double-blind trial of solifenacin in overactive bladder (OAB), cystospasm and urinary bladder diseases (3 arms), sponsored by Astellas Pharma. Primary endpoints: Change in bladder wall thickness and Change in urinary nerve growth factor levels. Started Apr 2012; status: completed.
02
Drugs
solifenacin
03
Conditions
overactive bladder (OAB)cystospasmurinary bladder diseases
Beyond the preview
Go deeper on DRKS00003889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003889.